Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E9KA
|
|||
| Former ID |
DNAP001269
|
|||
| Drug Name |
Ingenol mebutate
|
|||
| Synonyms |
Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Approved | [1], [2], [3] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [4] | ||
| Company |
LEO Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H34O6
|
|||
| Canonical SMILES |
CC=C(C)C(=O)OC1C(=CC23C1(C(C(=CC(C2=O)C4C(C4(C)C)CC3C)CO)O)O)C
|
|||
| InChI |
1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
|
|||
| InChIKey |
VDJHFHXMUKFKET-WDUFCVPESA-N
|
|||
| CAS Number |
CAS 75567-37-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:66913
|
|||
| ADReCS Drug ID | BADD_D01158 | |||
| SuperDrug ATC ID |
D06BX02
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7443). | |||
| REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | ClinicalTrials.gov (NCT01546571) Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.